首页> 美国卫生研究院文献>Springer Open Choice >Thyroid cancer: SEOM clinical guidelines
【2h】

Thyroid cancer: SEOM clinical guidelines

机译:甲状腺癌:SEOM临床指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thyroid cancer (TC) is the most common type of endocrine malignancy and accounts for nearly 3 % of all malignancies. The incidence of TC in Spain was 5/100,000 in women and 1.9/100,000 in men in 2013. The diagnosis of TC usually follows the identification of a thyroid nodule on physical examination or as an incidental finding on diagnostic imaging performed for other reasons. In most of the cases, the prognosis is excellent but despite low mortality rates, local recurrence occurs in up to 20 %, and distant metastases can occur in approximately 10 % at 10 years. The better knowledge of molecular biology of TC has allowed to the development of new targeted agents directed to the main pathways involved in TC pathogenesis. Knowing all these new strategies will help us face the therapeutic management of TC more effectively.
机译:甲状腺癌(TC)是最常见的内分泌恶性肿瘤,约占所有恶性肿瘤的3%。 2013年,西班牙的TC发病率为5 / 100,000,女性为1.9 / 100,000,男性为TC。通常在体格检查后发现甲状腺结节或出于其他原因在诊断成像中偶然发现TC。在大多数情况下,预后良好,但是尽管死亡率低,但局部复发率高达20%,并且在10年时远处转移可能发生率约为10%。对TC分子生物学的深入了解已导致开发针对TC发病机理的主要途径的新型靶向药物。了解所有这些新策略将有助于我们更有效地面对TC的治疗管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号